{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-108292","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.733975+00:00","generated_at":"2026-05-15T11:47:32.084061+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cue Biopharma reports Q4 net income of $1.6M on $21.9M collab revenue from ImmunoScape; cash $27.1M","bullets":["Net income $1.585M ($0.01 EPS) in Q4 2025 vs net loss $9.496M in Q4 2024; full-year net loss $26.6M vs $40.7M.","Collaboration revenue $21.9M in Q4 vs $1.6M; primarily from $9.5M upfront from ImmunoScape deal, with $5M due Nov 2026.","R&D expenses $16.5M (up from $7.2M) on CUE-401 mfg and ImmunoScape-related costs; G&A $3.5M (down from $4.0M).","Appointed Lucinda Warren CFO; raised $10.2M net in public offering; cash $27.1M at Dec 31, 2025.","Advanced CUE-401 autoimmune drug toward IND; reported preclinical safety data; plans Virtual R&D Day."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-108292","json":"https://secwatch.observer/filing/0001193125-26-108292.json","markdown":"https://secwatch.observer/filing/0001193125-26-108292.md","text":"https://secwatch.observer/filing/0001193125-26-108292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/0001193125-26-108292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/cue-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:47:32.084061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a97c7f1c10a09d4890f05651efde0239ef67afb","claim":"Cue Biopharma, Inc. reported the year ended December 31, 2025 results: revenue $27.5 million.","evidence_excerpt":"The Company reported collaboration revenue of $27.5 million and $9.3 million for the years ended December 31, 2025 and 2024, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/0001193125-26-108292-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$27.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c052616365d031d3aa95bf0cf37f378de9ffc315","claim":"Cue Biopharma, Inc. reported the three months ended December 31, 2025 results: revenue $21.9 million.","evidence_excerpt":"The Company reported collaboration revenue of $21.9 million and $1.6 million for the three months ended December 31, 2025 and 2024, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/0001193125-26-108292-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2025"},{"label":"Revenue","value":"$21.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}